Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodohippurate sodium I-131 is a radiopharmaceutical small molecule consisting of the organic compound iodohippuric acid labeled with radioactive iodine isotope (Iodine-131). It is primarily used as a diagnostic agent to evaluate renal plasma flow and kidney function. The mechanism of action involves its rapid filtration and secretion by the kidneys, allowing for assessment of renal perfusion and excretory capacity using gamma camera imaging. The radioisotope emits both beta and gamma radiation; the gamma emissions enable imaging while the beta emissions contribute to tissue effects. This agent is not typically used for therapeutic purposes but rather for functional diagnostics in nuclear medicine[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iodohippurate sodium I-131.